Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis

Mingming Hu, Ying Hu, Jiabei He, Baolan Li, Mingming Hu, Ying Hu, Jiabei He, Baolan Li

Abstract

Background: Basic fibroblast growth factor (bFGF) is known to stimulate angiogenesis and thus to influence the proliferation, migration and survival of tumor cells. Many studies examined the relationship between human bFGF overexpression and survival in lung cancer patients, but the results have been mixed. To systematically summarize the clinical prognostic function of bFGF in lung cancer, we performed this systematic review with meta-analysis.

Method: Studies were identified by an electronic search of PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang databases, including publications prior to August 2014. Pooled hazard ratios (HR) for overall survival (OS) were aggregated and quantitatively analyzed by meta-analysis.

Results: Twenty-two studies (n = 2154) were evaluated in the meta-analysis. Combined HR suggested that bFGF overexpression had an adverse impact on survival of patients with lung cancer(HR = 1.202,95%CI, 1.022-1.382). Our subgroup analysis revealed that the combined HR evaluating bFGF expression on OS in operable non-small cell lung cancer (NSCLC) was 1.553 (95%CI, 1.120-1.986); the combined HR in small cell lung cancer (SCLC) was 1.667 (95%CI, 1.035-2.299). There was no significant impact of bFGF expression on survival in advanced NSCLC.

Conclusion: This meta-analysis showed that bFGF overexpression is a potential indicator of worse prognosis for patients with operable NSCLC and SCLC, but is not associated with outcome in advanced NSCLC. The data suggests that high bFGF expression is highly related to poor prognosis. Nevertheless,more high-quality studies should be performed in order to provide additional evidence for the prognostic value of bFGF in lung cancer.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow chart of studies included…
Fig 1. Flow chart of studies included in this meta-analysis.
Fig 2. Sensitivity analysis for combined HRs…
Fig 2. Sensitivity analysis for combined HRs evaluating bFGF expression on OS.
Fig 3. Forest plots of OS associated…
Fig 3. Forest plots of OS associated with bFGF expression in lung cancer.
Fig 4. Forest plots of OS assessing…
Fig 4. Forest plots of OS assessing bFGF expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Fig 5. Forest plots of OS assessing…
Fig 5. Forest plots of OS assessing bFGF expression in operable NSCLC advanced NSCLC.
Fig 6. Forest plots of OS assessing…
Fig 6. Forest plots of OS assessing bFGF expression in retrospective studies and prospective studies.

References

    1. McMillen E, Ye F, Li G, Wu Y, Yin G, Liu W. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res 2010;36:531–7. 10.3109/01902148.2010.482176
    1. Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013; 4:2–10.
    1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
    1. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998;95:14389–94.
    1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235–53. 10.1038/nrd2792
    1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116–29. 10.1038/nrc2780
    1. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:263–7.
    1. Eto H, Suga H, Aoi N, Kato H, doi K,Kuno S, et al. Therapeutic potential of fibroblast growth factor-2 for hypertrophic scars: upregulation of MMP-1 and HGF expression. Lab Invest 2012;92:214–23. 10.1038/labinvest.2011.127
    1. Kim HR, Heo YM, Jeong KI, Kim YM, Jang HL, LEE KY, et al. FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep 2012;45:287–92.
    1. Xiao D, Wang K, Zhou J, Cao H, Deng Z, Hu Y, et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2008;40:297–303.
    1. Nishida T, Kubota S, Aoyama E, Janune D, Maeda A, Takigawa M. Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes. Endocrinology 2011;152:4232–41. 10.1210/en.2011-0234
    1. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705–19.
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16
    1. Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamanoto Y, Yamanoto T, et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 1996; 32A:1504–9.
    1. Ito H, Oshita F, Kameda Y, Suzuki R, Ikehara M, Aria H, et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep 2002;9:119–23.
    1. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.Cancer 2002. February 15;94(4):1083–93.
    1. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol 2014;9:848–55.
    1. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008;14:1407–12. 10.1158/1078-0432.CCR-07-1154
    1. Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18:1123–7.
    1. Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002;62:5210–7.
    1. Garpenstrand H, Bergqvist M, Brattström D, Larsson A, Oreland L, Hesselius P, et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients. Med Oncol 2004;21:241–50.
    1. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004;25:443–8.
    1. Zhou T, Pan TC. Correlation of angiogenesis with expression of basic fibroblast growth factor and its receptor in lung cancer. Academic Dissertation, Tongji Medical College, Huazhong University of Science and Technology, 2004.
    1. Yu M, Li SY, Yu Z, Qiu XS, Hou P, Wang EH, et al. Clinical significance of heparanase and basic fibroblast growth factor expression in human non-small cell lung cancer. Chinese Journal of Pathology 2005;34:36–41.
    1. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009; 4:578–85. 10.1097/JTO.0b013e31819f2e38
    1. Brattström D, Bergqvist M, Hesselius P, Larsson A, lamberg K, Wernlund J, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002;37:57–63.
    1. Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, et al. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 2011;73:366–74. 10.1016/j.lungcan.2011.01.002
    1. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 2001;85:1706–12.
    1. Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17:1190–9. 10.1158/1078-0432.CCR-10-2331
    1. Rades D, Setter C, Dahl O, Schild SE, Noack F. Fibroblast growth factor 2—a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;82:442–7. 10.1016/j.ijrobp.2010.08.048
    1. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008; 14:6014–22. 10.1158/1078-0432.CCR-08-0167
    1. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001;31:213–9.
    1. Ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1492–5.
    1. Jiang W, Cao JY, Pan B, Yu Y. Clinical significance of serum vascular endothelial growth factor and b-fibroblast growth factor before and after chemotherapy in patients with small cell lung cancer. Chinese Journal of Clinical Oncology 2013;40:638–642.
    1. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006–11. 10.1200/JCO.2009.23.7545
    1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116–29. 10.1038/nrc2780
    1. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 2009;20:225–34. 10.1684/ecn.2009.0175
    1. Gyanchandani R, Ortega Alves MV, Myers JN, Kim S. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol Cancer Res. 2013; 11:1585–96. 10.1158/1541-7786.MCR-13-0358
    1. Semrad TJ, Mack PC. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer. 2012; 13:90–5. 10.1016/j.cllc.2011.08.001
    1. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009;69:8645–51. 10.1158/0008-5472.CAN-09-1576
    1. Middleton KK, Barro V, Muller B, Terada S, Fu FH. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop J. 2012;32:150–63.
    1. Dyduch G, Kaczmarczyk K, Okoń K. Mast cells and cancer: enemies or allies? Pol J Pathol. 2012;63:1–7.
    1. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75 10.3389/fphys.2014.00075
    1. Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost. 2010;104:875–85. 10.1160/TH10-01-0017
    1. Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012;84:149–60. 10.1016/j.critrevonc.2012.02.012

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner